Somnomed Limited released unaudited fourth quarter & FY 18 results

snore sleep breath

FY 18 Unaudited Financial Performance: Somnomed Limited (ASX: SOM) has a market capitalization of 146.81 million and its stock has surged 13.62% on July 25, 2018 after the company reported for FY 18 result entailing revenue growth of 30% after delivering 22% revenue growth for the fourth quarter 2018 to $64.2 million (unaudited). For the fourth quarter, net operating cash flow is negative to $738,000, as a result at the end of June 2018, with the cash position of the company at $13.4 million. Excluding the investments made in RSS during the fourth quarter, the company has positive cash quarter for SOM’s core business to $3.26 million. Moreover, during the fourth quarter, the revenue growth for North America is 12%, for Europe 33% and 10% for APAC. SOM’s Core North America is facing challenging environment as in Q4 the growth fell by 9% compared to 7% growth in the third quarter. Additionally, for the full year, the group EBITDA is expected to decline to the lower end of the range of $6.6 million to $7.4 million. However, SOM’s core division EBITDA is expected to be at the upper end of the range $3.5 million to $3.8 million. In FY 19, the revenue is expected to grow at least 15%. Meanwhile, SOM stock has fallen 28.76% in three months as on July 24, 2018.

[pluginops_form template_id=’23834′ ]


Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report